Golden logoGolden logo
Advanced Search
LabGenius

LabGenius

Synthetic biology company that uses AI, DNA synthesis, and robotics to discover biological molecules.

LabGenius is a privately held, synthetic biology company based in London, UK. It uses a combination of artificial intelligence, DNA synthesis, and robotics to discover high-value biological molecules.

The company's novel technology is able to produce trillions of variations of gene sequences, which can be used to create new biological materials using artificial intelligence. It can predict which gene mutations will improve a biological design, thereby enabling scientists to produce new therapeutics or other materials such as adhesives, catalysts, and sensors.

LabGenius, in partnership with leading multinationals, is developing various products, focusing on the areas of biotherapeutics, advanced materials, and personal care. In the biotherapeutics category, LabGenius' AI-driven evolution engine, EVA, is learning how to optimally enhance the stability of therapeutic proteins in protease rich environments such as the GI tract, tumor microenvironments, and inflammed tissues. The end goal is to enable the delivery of novel therapies for unmet clinical needs.

In the advanced materials area, engineered proteins can be used to form high value coatings, adhesives, fibres, catalysts, and sensors. LabGenius has completed several development projects in this area and are engaged in collaborative development with aerospace and defence companies.

Timeline

October 2020
LabGenius raises a $15,000,000 series A round from Atomico, Kindred Capital, Obvious Ventures and iNovia Capital.
October 23, 2019
LabGenius raises a $10,000,000 series A round.
November 24, 2017
LabGenius raises $3.66m of investment
November 2017
LabGenius raises a $3,700,000 seed round from Ahmad Butt, BACKED VC, Beast Ventures, Berggruen Holdings, Champion Hill Labs, Charlie Songhurst, Kindred Capital, System.One, Tiny Super Computer Investment Company and Tom McInerney.
2012
LabGenius was founded by James Field.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

Contact us - LabGeni

Web

LabGenius Locks Down $3.66m From Top-Tier Investors To Harness Evolution - SynBioBeta

Web

News

Title
Author
Date
Publisher
Description
Steve O'Hear
October 22, 2019
TechCrunch
LabGenius, a London-based startup applying AI and "robotic automation" to protein drug discovery, has raised $10 million in Series A funding. The round is led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Air Street Capital and existing investors. Also investing is Recursion Pharmaceuticals' founder and CEO Chris Gibson, as [...]

References

Golden logo
By using this site, you agree to our Terms of Service.